Currently, there are 413.02M common shares owned by the public and among those 302.78M shares have been available to trade.
The company’s stock has a 5-day price change of 1.79% and -28.39% over the past three months. AGL shares are trading 19.47% year to date (YTD), with the 12-month market performance down to -63.62% lower. It has a 12-month low price of $1.50 and touched a high of $7.73 over the same period. AGL has an average intraday trading volume of 5.86 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.42%, -39.03%, and -30.18% respectively.
Institutional ownership of Agilon Health Inc (NYSE: AGL) shares accounts for 73.47% of the company’s 413.02M shares outstanding.
It has a market capitalization of $939.67M and a beta (3y monthly) value of 0.14. The earnings-per-share (ttm) stands at -$0.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.01% over the week and 7.62% over the month.
Analysts forecast that Agilon Health Inc (AGL) will achieve an EPS of -0.1 for the current quarter, -0.09 for the next quarter and -0.22 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.16 while analysts give the company a high EPS estimate of -0.16. Comparatively, EPS for the current quarter was -0.07 a year ago. Earnings per share for the fiscal year are expected to increase by 45.00%, and 33.31% over the next financial year. EPS should grow at an annualized rate of 41.90% over the next five years, compared to 3.29% over the past 5-year period.
Looking at the support for the AGL, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on April 25, 2025, with the firm’s price target at $5. Bernstein coverage for the Agilon Health Inc (AGL) stock in a research note released on April 08, 2025 offered a Outperform rating with a price target of $8.50. Macquarie on their part issued Neutral rating on December 16, 2024.
